Press Releases
Dec 17, 2021

Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP)...

Dec 14, 2021

Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D, "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,...

Dec 1, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., "Dyno") today announced an option and...

EXPLORE ALL US PRESS RELEASES

Articles
Dec 15, 2021

In our ongoing commitment to better serve patients through development of innovative therapies that address unmet needs, Astellas is proud to share recent top leadership appointments across our...

Nov 16, 2021

Astellas was recognized in Seramount’s 2021 Top 75 Companies for Executive Women list. Seramount announced its annual list of the 2021 Top 75 Companies for Executive Women and has included...

Nov 2, 2021

Clinical trials are a crucial step in drug development to find out if an experimental treatment is safe and effective in treating a specific condition or disease. But clinical trials also trigger...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products